{"schema_version":"secwatch.filing_event.v1","accession":"0001651308-23-000066","form_type":"8-K","ticker":"ONC","cik":"0001651308","company_name":"BeOne Medicines Ltd.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.844329+00:00","generated_at":"2026-06-15T22:15:10.483660+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BeiGene Q1 product revenue $410.3M (+57% YoY); BRUKINSA sales double to $211.4M","bullets":["Net loss narrowed to $348.4M ($0.26 per share) from $435.2M a year ago; operating leverage improved.","Global BRUKINSA sales of $211.4M, up 103% YoY, driven by U.S. CLL/SLL launch ($138.8M U.S.).","Tislelizumab revenue in China $114.9M (+31% YoY); 10 approved indications in China.","Cash and short-term investments $3.8B as of March 31, 2023; operating cash outflow $563.8M in Q1.","R&D expenses $408.6M; SG&A $328.5M; gross margin improved to 80.1% from 75.1%."],"urls":{"canonical":"https://secwatch.observer/filing/0001651308-23-000066","json":"https://secwatch.observer/filing/0001651308-23-000066.json","markdown":"https://secwatch.observer/filing/0001651308-23-000066.md","text":"https://secwatch.observer/filing/0001651308-23-000066.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651308/000165130823000066/0001651308-23-000066-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651308/000165130823000066/bgne-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T22:15:10.483660+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a1ab789068b6aa581647c12891f575cfbf5036f4","claim":"BeOne Medicines Ltd. reported the three months ended March 31, 2023 results: revenue $447.8 million, net income $348.4 million, EPS $0.26 per share.","evidence_excerpt":"faster than operational expenses, BeiGene is well positioned for future growth.” First Quarter 2023 Financial Results Revenue for the three months ended March 31, 2023, was $447.8 million, compared to $306.6 million in the same period of 2022. • Product revenue totaled $410.3 million for the three months ended March 31, 2023, compared to $261.6 million in the same","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1651308/000165130823000066/0001651308-23-000066-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Revenue","value":"$447.8 million"},{"label":"Net income","value":"$348.4 million"},{"label":"EPS","value":"$0.26 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}